Cybin Inc. Announces Leadership Transition with Co-Founder Eric So Appointed Interim CEO
TL;DR
Cybin's CEO transition positions interim leader Eric So to accelerate clinical pipeline development, potentially gaining competitive advantage in neuropsychiatry treatments.
Cybin's structured leadership change involves a board committee search for a new CEO while So focuses on advancing Phase 3 CYB003 and Phase 2 CYB004 trials.
Cybin's leadership continuity ensures continued development of novel mental health treatments that could revolutionize care for millions suffering from depression and anxiety.
Cybin develops deuterated psychedelic analogs like CYB003 for depression, showing how ancient compounds are being reinvented for modern mental health treatment.
Found this article helpful?
Share it with your network and spread the knowledge!
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) has announced a significant leadership transition effective September 2, 2025, with Doug Drysdale stepping down as Chief Executive Officer. Co-founder and President Eric So has been appointed as interim CEO to lead the company during this period of change. The Board of Directors has established a committee to conduct a comprehensive search for a permanent CEO who will guide Cybin through its commercialization phase.
This leadership change comes at a critical juncture for Cybin, a late-stage neuropsychiatry company focused on developing innovative treatments for mental health conditions. The company's clinical pipeline includes promising investigational compounds that have shown class-leading data in addressing the substantial unmet needs in mental healthcare. So's interim leadership will focus specifically on advancing Cybin's key clinical programs, including CYB003 and CYB004, while maintaining operational continuity during the transition period.
CYB003, Cybin's proprietary deuterated psilocin analog, represents a significant advancement in mental health treatment. The compound is currently in Phase 3 studies for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This designation accelerates the development and review process for drugs that demonstrate substantial improvement over existing therapies for serious conditions. More information about the company's developments can be found at https://ibn.fm/CYBN.
Additionally, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule currently in Phase 2 study for generalized anxiety disorder. The company maintains a research pipeline of investigational compounds focused on 5-HT receptors, positioning itself at the forefront of neuropsychiatry innovation. Founded in 2019, Cybin operates across multiple countries including Canada, the United States, the United Kingdom, and Ireland, reflecting its global approach to addressing mental health challenges.
The leadership transition and ongoing clinical developments have significant implications for the mental health treatment landscape. With millions of people worldwide suffering from mental health conditions and existing treatments often providing inadequate relief, Cybin's novel therapeutic approaches could potentially revolutionize patient care. The interim leadership under Eric So, who brings foundational knowledge of the company's vision and operations, ensures that critical research and development milestones continue uninterrupted while the board searches for a permanent CEO to lead commercialization efforts.
Curated from InvestorBrandNetwork (IBN)
